

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4939862

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALI SHILATIFARD	04/24/2018
EDWIN SMITH	04/24/2018
KAIWEI LIANG	04/24/2018
RECEIVING PARTY DATA	
Name:	NORTHWESTERN UNIVERSITY
Street Address:	633 CLARK STREET
City:	EVANSTON
State/Country:	ILLINOIS
Postal Code:	60208
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15497783
CORRESPONDENCE DATA	
Fax Number:	(414)271-5770
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(414) 271-7590
Email:	heatherb@andruslaw.com
Correspondent Name:	ANDRUS INTELLECTUAL PROPERTY LAW, LLP
Address Line 1:	100 E. WISCONSIN AVE.
Address Line 2:	SUITE 1100
Address Line 4:	MILWAUKEE, WISCONSIN 53202
ATTORNEY DOCKET NUMBER:	5369-00375
NAME OF SUBMITTER:	M. SCOTT MCBRIDE
SIGNATURE:	/M. Scott McBride/
DATE SIGNED:	05/01/2018
Total Attachments: 5	
source=2018-05-01_5369-00375_Executed_Assignment#page1.tif	
source=2018-05-01_5369-00375_Executed_Assignment#page2.tif	
source=2018-05-01_5369-00375_Executed_Assignment#page3.tif	

source=2018-05-01_5369-00375_Executed_Assignment#page4.tif

source=2018-05-01_5369-00375_Executed_Assignment#page5.tif

ASSIGNMENT

U.S. Serial No: 15/497,783 Filing Date: April 26, 2017
Inventors: Ali Shilatifard; Edwin Smith; Kaiwei Liang
Title of U.S. Patent Application: THERAPEUTIC TARGETING OF INTERLEUKIN-1
RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY
REARRANGEMENTS IN THE
MIXED LINEAGE LEUKEMIA GENE (MLL-r)

For good and valuable consideration, the receipt and sufficiency of which are hereby agreed, each of the undersigned hereby assigns to Northwestern University, an Illinois not-for-profit corporation, having a place of business at 633 Clark Street, Evanston, Illinois 60208 and its successors and assigns ("Assignee") the entire right, title and interest in and to the inventions of such undersigned disclosed in the application listed above, and in any and all other applications anywhere in the world which the undersigned may file and/or be named as an inventor of, solely or jointly, on said inventions, in any and all patents which may be obtained on any of said applications and in any and all reissues, reexaminations, supplemental examinations, inter partes reviews, oppositions, post-grant reviews, supplementary protection certificates and/or extensions thereof, including without limitation, the right to bring suit and to claim and retain all damages and/or seek other remedies for the past, present and future infringement of any of the foregoing, the right of priority, including without limitation to claim priority benefit of or to said patent applications, and request the Commissioner for Patents in the United States and similar authorities outside the United States to issue said patents to and in the name of the Assignee.

Each of the undersigned states that the application listed above is or was made or authorized to be made by him or her. Each of the undersigned believes himself or herself to be the original inventor or a joint inventor with another undersigned of a claimed invention in the application listed above. Each of the undersigned acknowledges that any willful false statement made by him or her in this paragraph is punishable under 18 U.S.C. §1001 by fine or imprisonment of not more than five years, or both.

Except in favor of Assignee, each of the undersigned warrants that: (i) he or she is the owner of all its rights, titles and interests herein assigned and has the right to make this unconditional and irrevocable assignment to Assignee without obtaining any approval or permission of a third party; and (ii) there are no outstanding encumbrances, liens, prior assignments, licenses, or other obligations or restrictions on the rights, titles and interests herein assigned.


Upon the request of Assignee and at no expense to the undersigned, each of the undersigned hereby agrees to execute any and all applications on said inventions, including without limitation for the reissue, reexamination, supplementary protection certificate or extension thereof and any oath, declaration or affidavit relating thereto that said Assignee may deem necessary or expedient, and to cooperate to the best of the ability of the undersigned with and perform any and all affirmative acts requested by Assignee to prepare, file, prosecute, maintain, defend, enforce and vest in Assignee the rights, titles and interests assigned herein, including without limitation, preparing and executing statements and giving and producing evidence in support thereof, whereby said rights, titles and interests will be held and enjoyed by said Assignee to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made.

Undersigned (ASSIGNORS):

 April 24 - 2018
Inventor Name: Ali Shilatfard DATE


State of Illinois ss.
County of Cook

On this 24th day of April, 2018, before me, a Notary Public in and for the County and State aforesaid, appeared, to me personally known to be the same person whose name is subscribed to the foregoing instrument, and acknowledged that he or she executed said instrument as his or her free and voluntary act and for the uses and purposes therein expressed.


NOTARY PUBLIC

My Commission Expires: March 28, 2022

[NOTARY SEAL]



(Continued on next page)

U.S. Serial No: 15/497,783
Filing Date: April 26, 2017
Inventors: Ali Shilatifard; Edwin Smith; Kaiwei Liang
Title of U.S. Patent Application: THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)

Undersigned (ASSIGNORS) continued:

Edwin Smith 4/24/18
Inventor Name: Edwin Smith DATE


State of Illinois
County of Cook ss.

On this 24th day of April, 2018, before me, a Notary Public in and for the County and State aforesaid, appeared, to me personally known to be the same person whose name is subscribed to the foregoing instrument, and acknowledged that he or she executed said instrument as his or her free and voluntary act and for the uses and purposes therein expressed.

Beverly Kirk
NOTARY PUBLIC

[NOTARY SEAL]

My Commission Expires: March 28, 2022



U.S. Serial No: 15/497,783
Filing Date: April 26, 2017
Inventors: Ali Shafatfard; Edwin Smith; Kaiwei Liang
Title of U.S. Patent Application: THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-
ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN
THE
MIXED LINEAGE LEUKEMIA GENE (MLL-r)

Undersigned (ASSIGNORS) continued:

Liangwei Apr 24/2018
Inventor Name: Kaiwei Liang DATE


State of Illinois ss.
County of Cook

On this 24th day of April 2018, before me, a Notary Public in and for the County
and State aforesaid, appeared, to me personally known to be the same person whose name is subscribed to
the foregoing instrument, and acknowledged that he or she executed said instrument as his or her free and
voluntary act and for the uses and purposes therein expressed.

[Signature]
NOTARY PUBLIC

[NOTARY SEAL]

My Commission Expires: March 28, 2022



U.S. Serial No: 15/497,783
Filing Date: April 26, 2017
Inventors: Ali Shilatifard; Edwin Smith; Kaiwei Liang
Title of U.S. Patent Application: THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)

ASSIGNEE ACCEPTANCE: Northwestern University:

On behalf of Northwestern University, Assignee, the authorized signatory below, hereby confirms Assignee's acceptance of all rights, privileges, titles and interests conveyed by this Assignment.

Authorized Signature: 

Date: 30 Apr 2018

Printed Name Beverly R. Milligan, Invention Specialist or
Nicole A. Janovick, Ph.D., J.D., Invention Manager

Department: Innovation and New Ventures Office (INVO)